Consistent safety and tolerability across bipolar depression and schizophrenia trials in adults1,2

Across 3 indications, CAPLYTA was similar to placebo in1,2*:

  • Extrapyramidal symptoms
  • Akathisia
  • Metabolic effects
  • Prolactin levels
  • Weight change

*Based on data from individual studies that were 4- to 6-weeks in duration.

Antipsychotic drugs have been reported to cause:

  • Tardive Dyskinesia (TD), a syndrome of potentially irreversible, dyskinetic, and involuntary movements which may increase as the duration of treatment and total cumulative dose increases. The syndrome can develop after a relatively brief treatment period, even at low doses, or after treatment discontinuation. Given these considerations, CAPLYTA should be prescribed in a manner most likely to reduce the risk of TD. Discontinue CAPLYTA if clinically appropriate.
  • Metabolic Changes, including hyperglycemia, diabetes mellitus, dyslipidemia, and weight gain. Hyperglycemia, in some cases extreme and associated with ketoacidosis, hyperosmolar coma or death, has been reported in patients treated with antipsychotics. Measure weight and assess fasting plasma glucose and lipids when initiating CAPLYTA and monitor periodically during long-term treatment.

Please see additional Important Safety Information, including Boxed Warnings, below.

CAPLYTA demonstrated safety in 2,664 adult patients with bipolar depression and schizophrenia1

  • In clinical studies, there was no single adverse reaction leading to discontinuation that occurred at a rate of >2% in patients treated with CAPLYTA.1
  • In bipolar depression trials, the most common adverse reactions with CAPLYTA vs placebo were (monotherapy, adjunctive therapy): somnolence/sedation (13% vs 3%, 13% vs 3%), dizziness (8% vs 4%, 11% vs 2%), nausea (8% vs 3%, 9% vs 4%), and dry mouth (5% vs 1%, 5% vs 1%). Somnolence was predominantly mild.1
  • In schizophrenia trials, the most common adverse reactions with CAPLYTA vs placebo were somnolence/sedation (24% vs 10%) and dry mouth (6% vs 2%). Somnolence was predominantly mild.1

Antipsychotic drugs have been reported to cause:

  • Potential for Cognitive and Motor Impairment. Advise patients to use caution when operating machinery or motor vehicles until they know how CAPLYTA affects them.

Please see additional Important Safety Information, including Boxed Warnings, below.

Explore select safety data for each indication by selecting a tab below

EPS and akathisia

See the short-term and long-term data.

EPS and Akathisia

Weight and metabolic effects

See the short-term and long-term data in bipolar depression studies.

Weight & Metabolic Effects

Consistent safety and tolerability

In adults with bipolar I or bipolar II depression.

Most Common
Adverse Events

Frequently Asked Questions

What are the rates of adverse reactions related to sexual function?
There were low rates of adverse reactions related to sexual function2

Most common adverse reactions relating to sexual side effects reported in a 6-week bipolar depression trial2

Bipolar Depression

Monotherapy

Adjunctive
(with Lithium or Valproate)

Adverse reactions reported related to sexual side effects
CAPLYTA (n=372)
Placebo (n=374)
CAPLYTA (n=177)
Placebo (n=175)
Erectile dysfunction†
0.0%
0.7%
0.0%
0.0%
Libido decreased
1.1%
0.3%
0.6%
0.0%
Orgasm abnormal
0.3%
0.0%
0.0%
0.0%

Bipolar Depression

Monotherapy

Adverse reactions reported related to sexual side effects
CAPLYTA (n=372)
Placebo (n=374)
Erectile dysfunction†
0.0%
0.7%
Libido decreased
1.1%
0.3%
Orgasm abnormal
0.3%
0.0%

Bipolar Depression

Adjunctive
(with Lithium or Valproate)

Adverse reactions reported related to sexual side effects
CAPLYTA (n=177)
Placebo (n=175)
Erectile dysfunction†
0.0%
0.0%
Libido decreased
0.6%
0.0%
Orgasm abnormal
0.0%
0.0%

Most common adverse reactions relating to sexual side effects reported in 4- to 6-week schizophrenia trials2

Schizophrenia

Adverse reactions reported related to sexual side effects
CAPLYTA (n=406)
Placebo (n=412)
Erectile dysfunction†
0.7%
0.5%
Libido decreased
0.0%
0.0%
Erection increased
0.0%
0.0%
Spontaneous penile erection
0.0%
0.0%

Schizophrenia

Adverse reactions reported related to sexual side effects
CAPLYTA (n=406)
Placebo (n=412)
Erectile dysfunction†
0.7%
0.5%
Libido decreased
0.0%
0.0%
Erection increased
0.0%
0.0%
Spontaneous penile erection
0.0%
0.0%

†Represents male-specific treatment-emergent adverse events at 4- to 6-weeks.

Is CAPLYTA a controlled substance?
No, CAPLYTA is not a controlled substance.3
What is the impact of CAPLYTA on Cardiac Electrophysiology and/or QT interval?
CAPLYTA does not have a specific warning regarding QT interval prolongation in its US Prescribing Information. During its development, CAPLYTA was studied in a thorough QT study in 33 patients with schizophrenia. The placebo‑corrected change from baseline in the 42 mg dose was 4.9 msec with a 90% two‑sided upper confidence interval of 8.9 msec. In patients receiving a supratherapeutic dose of 126 mg of lumateperone (three times the recommended daily dose), the placebo‑corrected change from baseline was 15.8 msec with a 90% two‑sided upper confidence interval of 19.8 msec.1

CAPLYTA is indicated in adults for the treatment of schizophrenia and depressive episodes associated with bipolar I or II disorder (bipolar depression), as monotherapy and as adjunctive therapy with lithium or valproate.

Important Safety Information

Boxed Warnings:

  • Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. CAPLYTA is not approved for the treatment of patients with dementia-related psychosis.
  • Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adults in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening, and for emergence of suicidal thoughts and behaviors. The safety and effectiveness of CAPLYTA have not been established in pediatric patients.

Contraindications: CAPLYTA is contraindicated in patients with known hypersensitivity to lumateperone or any components of CAPLYTA. Reactions have included pruritus, rash (e.g., allergic dermatitis, papular rash, and generalized rash), and urticaria.

Warnings & Precautions: Antipsychotic drugs have been reported to cause:

  • Cerebrovascular Adverse Reactions in Elderly Patients with Dementia-Related Psychosis, including stroke and transient ischemic attack. See Boxed Warning above.
  • Neuroleptic Malignant Syndrome, which is a potentially fatal reaction. Signs and symptoms include hyperpyrexia, muscle rigidity, delirium, autonomic instability, elevated creatinine phosphokinase, myoglobinuria (and/or rhabdomyolysis), and acute renal failure. Manage with immediate discontinuation of CAPLYTA and provide intensive symptomatic treatment and monitoring.
  • Tardive Dyskinesia (TD), a syndrome of potentially irreversible, dyskinetic, and involuntary movements which may increase as the duration of treatment and total cumulative dose increases. The syndrome can develop after a relatively brief treatment period, even at low doses, or after treatment discontinuation. Given these considerations, CAPLYTA should be prescribed in a manner most likely to reduce the risk of TD. Discontinue CAPLYTA if clinically appropriate.
  • Metabolic Changes, including hyperglycemia, diabetes mellitus, dyslipidemia, and weight gain. Hyperglycemia, in some cases extreme and associated with ketoacidosis, hyperosmolar coma or death, has been reported in patients treated with antipsychotics. Measure weight and assess fasting plasma glucose and lipids when initiating CAPLYTA and monitor periodically during long-term treatment.
  • Leukopenia, Neutropenia, and Agranulocytosis (including fatal cases). Perform complete blood counts in patients with pre-existing low white blood cell count (WBC) or history of leukopenia or neutropenia. Discontinue CAPLYTA if clinically significant decline in WBC occurs in absence of other causative factors.
  • Orthostatic Hypotension and Syncope. Monitor heart rate and blood pressure and warn patients with known cardiovascular or cerebrovascular disease. Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension.
  • Falls. CAPLYTA may cause somnolence, postural hypotension, and motor and/or sensory instability, which may lead to falls and, consequently, fractures and other injuries. Assess patients for risk when using CAPLYTA.
  • Seizures. Use CAPLYTA cautiously in patients with a history of seizures or with conditions that lower seizure threshold.
  • Potential for Cognitive and Motor Impairment. Advise patients to use caution when operating machinery or motor vehicles until they know how CAPLYTA affects them.
  • Body Temperature Dysregulation. Use CAPLYTA with caution in patients who may experience conditions that may increase core body temperature such as strenuous exercise, extreme heat, dehydration, or concomitant anticholinergics.
  • Dysphagia. Use CAPLYTA with caution in patients at risk for aspiration.

Drug Interactions: Avoid concomitant use with CYP3A4 inducers. Reduce dose for concomitant use with strong CYP3A4 inhibitors (10.5 mg) or moderate CYP3A4 inhibitors (21 mg).

Special Populations: Neonates exposed to antipsychotic drugs during the third trimester of pregnancy are at risk for extrapyramidal and/or withdrawal symptoms following delivery. Reduce dose for patients with moderate or severe hepatic impairment (21 mg).

Adverse Reactions: The most common adverse reactions in clinical trials with CAPLYTA vs placebo were:

  • Schizophrenia: somnolence/sedation (24% vs 10%) and dry mouth (6% vs 2%).
  • Bipolar Depression (Monotherapy, Adjunctive therapy): somnolence/sedation (13% vs 3%, 13% vs 3%), dizziness (8% vs 4%, 11% vs 2%), nausea (8% vs 3%, 9% vs 4%), and dry mouth (5% vs 1%, 5% vs 1%).

CAPLYTA is available in 10.5 mg, 21 mg, and 42 mg capsules.

Indications

CAPLYTA is indicated in adults for the treatment of schizophrenia and depressive episodes associated with bipolar I or II disorder (bipolar depression), as monotherapy and as adjunctive therapy with lithium or valproate.

Please see full Prescribing Information, including Boxed Warnings.

References: 1. CAPLYTA prescribing information. 2. Data on File (REF-00361, REF-00363, REF-00364, REF-00793, REF-00794, REF-00813, REF-00903, REF-01380, REF-01470, REF-01533). 3. Controlled substances - alpha order - dea diversion control division. (n.d.). Accessed May 1, 2024. https://deadiversion.usdoj.gov/schedules/orangebook/c_cs_alpha.pdf.

Boxed Warnings:

  • Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. CAPLYTA is not approved for the treatment of patients with dementia-related psychosis.